By Fineline Cube 
China-based Huadong Medicine Co., Ltd. (SHE: 000963) announced that it has received clinical trial approval from China’s National Medical Products Administration (NMPA) for its investigational antibody fusion protein DR30206. The drug targets PD-L1, VEGF, and TGF-β and will be evaluated in combination with standard chemotherapy for advanced or metastatic gastrointestinal tumors.
Drug Profile
DR30206 is a multi-target antibody fusion protein designed to simultaneously inhibit PD-L1, VEGF, and TGF-β, pathways often dysregulated in cancer. Preclinical studies and early-phase trials have demonstrated promising antitumor activity and a favorable safety profile, supporting its potential as a novel therapeutic option.
Clinical Trial Objectives
The approved study will assess the safety, tolerability, and preliminary efficacy of DR30206 when combined with standard chemotherapy. This combination therapy aims to enhance treatment outcomes for patients with advanced gastrointestinal tumors, a population with significant unmet medical needs.-Fineline Info & Tech